European cancer mortality predictions for the year 2019 with focus on breast cancer

Malvezzi, Matteo; Carioli, Greta; Bertuccio, Paola; Boffetta, Paolo; Levi, Fabio; Vecchia, Carlo La; Negri, Eva

doi:10.1093/annonc/mdz051

Cited by 199 publications

(145 citation statements)

References 34 publications

Supporting

Mentioning

127

Contrasting

Unclassified

Order By: Relevance

“…We only mentioned in two lines a possible role of decrease in menopausal hormone use on national breast cancer rates [2]. Indeed, changes in hormonal replacement therapy (HRT) use had a relevant impact on incidence, but their influence on mortality is limited and not adequately quantified [3,4].…”

Section: And Hamoda On Behalf Of the British Menopause Society Medicmentioning

confidence: 99%

“…Local recurrence and survival after treatment are highly related to the degree of extramural spread within the T3 category with a heterogeneity far greater than for any other T stage, with local recurrence ranging from less than 10% to over 20%. Histopathological analysis of cancer-specific end points within the T3 category has shown that its division into pT3a and pT3b subgroups in which extramural spread is up to and including 5 mm in the former and more than 5 mm in the latter is the strongest locoregional prognostic factor of local recurrence and survival [1][2][3]. Staging pretreatment MRI now forms the basis for management planning for locoregional disease, including the decision to recommend chemoradiation and the subsequent assessment of tumour response when this is given.…”

Section: Extramural Spread Of Rectal Cancer and The Ajcc Cancer Stagimentioning

confidence: 99%

See 1 more Smart Citation

Reply to the letter to the editor ‘European cancer mortality predictions for the year 2019 with focus on breast cancer, by Malvezzi M et al’ by Marsden and Hamoda, On behalf of the British Menopause Society Medical Advisory Council

Malvezzi¹,

Carioli²,

Bertuccio

et al. 2019

Annals of Oncology

Self Cite

View full text Add to dashboard Cite

Section: And Hamoda On Behalf Of the British Menopause Society Medicmentioning

confidence: 99%

Section: Extramural Spread Of Rectal Cancer and The Ajcc Cancer Stagimentioning

confidence: 99%

Reply to the letter to the editor ‘European cancer mortality predictions for the year 2019 with focus on breast cancer, by Malvezzi M et al’ by Marsden and Hamoda, On behalf of the British Menopause Society Medical Advisory Council

Malvezzi¹,

Carioli²,

Bertuccio

et al. 2019

Annals of Oncology

Self Cite

View full text Add to dashboard Cite

“…As for pathological discrimination, 70% are nonsquamous, ie, adeno‐ or large cell carcinomas . In the Europe‐wide estimation for 2019, NSCLC will account for 23% and 15% of all cancer deaths in men and women, respectively . According to the eighth edition of the TNM classification stage III NSCLC summarizes a scope of diverse subentities.…”

Section: Introductionmentioning

confidence: 99%

Radiation dose escalation with modified fractionation schedules for locally advanced NSCLC: A systematic review

Zehentmayr¹,

Grambozov²,

Kaiser³

et al. 2020

Thoracic Cancer

View full text Add to dashboard Cite

Concomitant chemo-radiotherapy (cCRT) with 60 Gy in 30 fractions is the standard of care for stage 111 non-small cell lung cancer (NSCLC). With a median overall survival of 28.7 months at best and maximum locoregional control rates of 70% at two years, the prognosis for these patients is still dismal. This systematic review summarizes data on dose escalation by alternative fractionation, which has been explored as a primary strategy to improve both local control and overall survival over the past three decades. A Pubmed literature search was performed according to the PRISMA guidelines. Because of the large variety of radiation regimens total doses were converted to EQD 2,T . Only studies using an EQD 2,T of at least 49.5 Gy, which corresponds to the conventional 60 Gy in six weeks, were included. In a total of 3256 patients, the median OS was 17 months (range 7.4-30 months). While OS was better for patients treated after the year 2000 (P = 0.003) or with a mandatory 18 F-FDG-PET-CT in the diagnostic workup (P = 0.001), treatment sequence did not make a difference (P = 0.106). The most commonly reported toxicity was acute esophagitis (AE) with a median rate of 24% (range 0%-84%). AE increased at a rate of 0.5% per Gy increment in EQD 2,T (P = 0.016). Dose escalation above the conventional 60 Gy using modified radiation fractionation schedules and shortened OTT yield similar mOS and LRC regardless of treatment sequence with a significant EQD 2,T dependent increase in AE. Key pointsSignificant findings • Modified radiation dose escalation sequentially combined with chemotherapy yields similar outcome as concomitant treatment. • OS is better with the mandatory inclusion of FDG-PET-CT in the diagnostic work-up. • The risk of acute esophagitis increases with higher EQD 2,T . What this study adds • Chemo-radiotherapy (CRT) with modified dose escalation regimens yields OS and LC rates in the range of standard therapy regardless of treatment sequence. This broadens the database of curative options in patients who are not eligible concomitant CRT.

show abstract

“…Breast cancer is prevalent in 12% of women in the USA more than 2.5 million new cases of breast cancer were diagnosed in 2017 [19]. The rate for breast cancer declined by 35% in last 3 decades but number of deaths remains same [20]. The 3 most prevalent cancers in 2019 are prostate, colorectal and skin melanoma among males, and breast, uterine corpus, and colorectal among females [21].…”

Section: Introductionmentioning

confidence: 99%

Alternative Treatments for Cancer Prevention and Cure [Part 1]

Mohiuddin¹

2019

APCT

View full text Add to dashboard Cite

Many lay people along with some so called "key opinion leaders" have a common slogan "There's no answer for cancer". Again, mistake delays proper treatment and make situation worse, more often. Compliance is crucial to obtain optimal health outcomes, such as cure or improvement in QoL. Patients may delay treatment or fail to seek care because of high out-of-pocket expenditures. Despite phenomenal development, conventional therapy falls short in cancer management. There are two major hurdles in anticancer drug development: dose-limiting toxic side effects that reduce either drug effectiveness or the QoL of patients and complicated drug development processes that are costly and time consuming. Cancer patients are increasingly seeking out alternative medicine and might be reluctant to disclose its use to their oncology treatment physicians. But there is limited available information on patterns of utilization and efficacy of alternative medicine for patients with cancer. As adjuvant therapy, many traditional medicines shown efficacy against brain, head and neck, skin, breast, liver, pancreas, kidney, bladder, prostate, colon and blood cancers. The literature reviews non-pharmacological interventions used against cancer, published trials, systematic reviews and meta-analyses.

show abstract

European cancer mortality predictions for the year 2019 with focus on breast cancer

Cited by 199 publications

References 34 publications

Reply to the letter to the editor ‘European cancer mortality predictions for the year 2019 with focus on breast cancer, by Malvezzi M et al’ by Marsden and Hamoda, On behalf of the British Menopause Society Medical Advisory Council

Reply to the letter to the editor ‘European cancer mortality predictions for the year 2019 with focus on breast cancer, by Malvezzi M et al’ by Marsden and Hamoda, On behalf of the British Menopause Society Medical Advisory Council

Radiation dose escalation with modified fractionation schedules for locally advanced NSCLC: A systematic review

Alternative Treatments for Cancer Prevention and Cure [Part 1]

Contact Info

Product

Resources

About